JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 3, 2007; DOI: 10.1124/jpet.107.120709


0022-3565/07/3221-214-221$20.00
JPET 322:214-221, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.120709v1
322/1/214    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, G.
Right arrow Articles by Feller, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, G.
Right arrow Articles by Feller, D. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-EPHEDRINE
*PHENYLPROPANOLAMINE
*PSEUDOEPHEDRINE

NEUROPHARMACOLOGY

Pharmacological Effects of Ephedrine Alkaloids on Human {alpha}1- and {alpha}2-Adrenergic Receptor Subtypes

Guoyi Ma, Supriya A. Bavadekar, Yolande M. Davis, Shilpa G. Lalchandani, Rangaswamy Nagmani, Brian T. Schaneberg, Ikhlas A. Khan, and Dennis R. Feller

The National Center for Natural Products Research (G.M., R.N., B.T.S., I.A.K., D.R.F.), Department of Pharmacology (S.A.B., Y.M.D., S.G.L., D.R.F.), and Department of Pharmacognosy (I.A.K.), School of Pharmacy, University of Mississippi, University, Mississippi

Ephedra species of plants have both beneficial and adverse effects primarily associated with the presence of ephedrine alkaloids. Few reports have appeared that examine the direct actions of ephedrine alkaloids on human subtypes of adrenergic receptors (ARs). In the present study, ephedrine alkaloids were evaluated for their binding affinities on human {alpha}1A-, {alpha}1B-, {alpha}1D-, {alpha}2A-, {alpha}2B-, and {alpha}2C-AR subtypes expressed in HEK and Chinese hamster ovary cells. Cell-based reporter gene assays were used to establish functional activity of ephedrine alkaloids at {alpha}1A-, {alpha}2A-, and {alpha}2C-ARs. The data showed that ephedrine alkaloids did not activate {alpha}1- and {alpha}2-ARs and that they antagonized the agonist-mediated effects of phenylephrine and medetomidine on {alpha}1- and {alpha}2-ARs, respectively. As in the binding studies, 1R,2R- and 1R,2S-ephedrine showed greater functional antagonist activity than the 1S,2R- and 1S,2S-isomers. The rank order of affinity for the isomers was 1R,2R > 1R,2S > 1S,2R > 1S,2S. The rank order of potencies of alkaloids containing a 1R,2S-configuration was norephedrine ≥ ephedrine >> N-methylephedrine. These studies have demonstrated that orientation of the beta-hydroxyl group on the ethylamino side chain and the state of N-methyl substitution are important for {alpha}-AR binding and functional activity of the ephedrine alkaloids. In conclusion, the ephedrine isomers and analogs studied did not exhibit any direct agonist activity and were found to possess moderate antagonist activities on cloned human {alpha}-ARs. The blockade of presynaptic {alpha}2A- and {alpha}2C-ARs may have a pharmacological role in the direct actions of Ephedra alkaloids.


Received January 29, 2007; accepted April 2, 2007.

Address correspondence to: Dr. Dennis R. Feller, Department of Pharmacology, School of Pharmacy, The University of Mississippi, University, MS 38677. E-mail: dfeller{at}olemiss.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.